Potent Anti-Mesothelioma Activity by the Novel Naftopidil Analogue HUHS1015; Preclinical Evidence for Treatment

被引：0
|
作者：
Kuribayashi, Kozo [1 ]
Ieki, Ryuji [1 ]
Otsuki, Taiichiro [1 ]
Gotoh, Akinobu [2 ]
Tanaka, Akito [3 ]
Nishizaki, Tomoyuki [4 ]
Nakano, Takashi [1 ]
机构：
[1] Hyogo Coll Med, Dept Internal Med, Div Resp Med, Nishinomiya, Hyogo 6638501, Japan
[2] Hyogo Coll Med, Inst Adv Med Sci, Lab Cell & Gene Therapy, Nishinomiya, Hyogo 6638501, Japan
[3] Hyogo Univ Hlth Sci, Adv Med Res Ctr, Lab Chem Biol, Kobe, Hyogo, Japan
[4] Hyogo Coll Med, Dept Physiol, Nishinomiya, Hyogo 6638501, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
Naftopidil; anticancer drug; apoptosis; Malignant pleural mesotelioma (MPM);
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI25.03
引用
收藏
页码：S352 / S352
页数：1
相关论文
共 45 条
  • [31] MRG006A, a novel glypican-3-targeting antibody-drug conjugate, demonstrated potent anti-tumor activity and good safety profile in preclinical studies
    Wang, Yanchun
    Li, Hongfeng
    Shen, Hao
    Liu, Wenchao
    Liu, Shoujia
    Yin, Kequan
    Xu, Haili
    Cui, Xueyuan
    Li, Wei
    Liu, Wei
    Wu, Xiangyu
    Yang, Liu
    Ma, Tian
    Zhao, Zhongrun
    Wang, Jun
    Cui, Feifei
    Fang, Lei
    Qin, Minmin
    Hu, Chaohong
    CANCER RESEARCH, 2024, 84 (06)
  • [32] PRECLINICAL EVALUATION OF STAR0602, A NOVEL, FIRST-IN-CLASS ANTI-TCR VB TARGETED BISPECIFIC ANTIBODY WITH POTENT ANTI-TUMOR ACTIVITY FOR PD-1 REFRACTORY SOLID TUMORS
    Su, Zhen
    Gulley, James
    Schlom, Jeffrey
    Siu, Lillian
    Sullivan, Ryan
    Wherry, E. John
    Liu, Ke
    Donahue, Renee
    Katraggada, Madan
    Chopra, Rajesh
    Moisan, Jacques
    Hsu, Jonathan
    Tsai, Yo-Ting
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1388 - A1388
  • [33] HX301 (ON1232580) a novel kinase inhibitor with potent activity against CSF1R and FLT3, shows strong anti-AML activity in defined preclinical models
    An, Xiaoyu
    Li, Henry
    Xue, Linda
    Liu, Jinping
    Xiong, Lingxin
    Ke, Hang
    Chen, Cen
    Gao, Bing
    Zheng, Jia
    Bao, Zhengzheng
    Guo, Sheng
    Zhang, Lei
    Zhang, Faming
    CANCER RESEARCH, 2023, 83 (07)
  • [34] Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models
    Yang, Tao
    Ke, Hang
    Liu, Jinping
    An, Xiaoyu
    Xue, Jia
    Ning, Jinying
    Hao, Feng
    Xiong, Lingxin
    Chen, Cen
    Wang, Yueying
    Zheng, Jia
    Gao, Bing
    Bao, Zhengzheng
    Gong, Kefeng
    Zhang, Lei
    Zhang, Faming
    Guo, Sheng
    Li, Qi-Xiang
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [35] DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL 7-AMINO PYRAZOLOPYRIMIDINE COMPOUNDS POSSESSING POTENT ANTI-WOLBACHIA ACTIVITY FOR THE TREATMENT OF ONCHOCERCIASIS AND LYMPHATIC FILARIASIS
    McGillan, Paul
    Berry, Neil G.
    Hong, David W.
    Cassidy, Andy
    Clare, Rachel
    Cook, Darren
    Johnston, Kelly
    Ward, Stephen
    O'Neill, Paul M.
    Taylor, Mark
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 95 (05): : 348 - 348
  • [36] Possible Repositioning of an Oral Anti-Osteoporotic Drug, Ipriflavone, for Treatment of Inflammatory Arthritis via Inhibitory Activity of KIAA1199, a Novel Potent Hyaluronidase
    Koike, Hiroshi
    Nishida, Yoshihiro
    Shinomura, Tamayuki
    Ohkawara, Bisei
    Ohno, Kinji
    Zhuo, Lisheng
    Kimata, Koji
    Ushida, Takahiro
    Imagama, Shiro
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (08)
  • [37] Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models
    Nakayama, Ayako
    Nagashima, Takeyuki
    Nishizono, Yoshihiro
    Kuramoto, Kazuyuki
    Mori, Kenichi
    Homboh, Kazuya
    Yuri, Masatoshi
    Shimazaki, Masashi
    BRITISH JOURNAL OF CANCER, 2022, 126 (05) : 744 - 753
  • [38] Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models
    Ayako Nakayama
    Takeyuki Nagashima
    Yoshihiro Nishizono
    Kazuyuki Kuramoto
    Kenichi Mori
    Kazuya Homboh
    Masatoshi Yuri
    Masashi Shimazaki
    British Journal of Cancer, 2022, 126 : 744 - 753
  • [39] JDQ443, a covalent irreversible inhibitor of KRAS G12C, exhibits a novel binding mode and demonstrates potent anti-tumor activity and favorable pharmacokinetic properties in preclinical models
    Brachmann, Saskia M.
    Weiss, Andreas
    Guthy, Daniel A.
    Beyer, Kim
    Voshol, Johannes
    Maira, Michel
    Prahallad, Anirudh
    Porta, Diana Graus
    Schnell, Christian
    Ostermann, Nils
    Vaupel, Andrea
    Gerspacher, Marc
    Leblanc, Catherine
    Erdmann, Dirk
    Sterker, Dario
    Kerr, Grainne
    Jerome, Giovannoni
    Head, Victoria
    Stringer, Rowan
    De Kanter, Ruben
    Jeff, Kearns
    Roman, Danielle
    Widmer, Toni
    Wessels, Peter
    Nunez, Eloisa Jimenez
    Sedrani, Richard
    Zecri, Frederic
    Hofmann, Francesco
    Engleman, Jeff
    Lorthiois, Edwige
    Cotesta, Simona
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [40] Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors
    Decary, Stephanie
    Berne, Pierre-Francois
    Nicolazzi, Celine
    Lefebvre, Anne-Marie
    Dabdoubi, Tarik
    Cameron, Beatrice
    Rival, Pierrick
    Devaud, Catherine
    Prades, Catherine
    Bouchard, Herve
    Casse, Alhassan
    Henry, Christophe
    Amara, Celine
    Brillac, Claire
    Ferrari, Paul
    Macon, Laetitia
    Lacoste, Eric
    Combeau, Cecile
    Beys, Eric
    Naimi, Souad
    Garcia-Echeverria, Carlos
    Mayaux, Jean-Francois
    Blanc, Veronique
    CLINICAL CANCER RESEARCH, 2020, 26 (24) : 6589 - 6599
12345